The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 2×
“The contact site mutants, for example, R248W and R273H, have an altered residue at a site that, in the wild-type protein, directly contacts DNA (Cho et al., 1994; Rolley et al., 1995).”
BackgroundKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Fort, P., Marty, L., Piechaczyk, M., Sabrouty, S. E., Dani, C., Jeanteur, P., & Blanchard, J. M. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.5.1431 · Cited by 2,099
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Nelson, W. G., & Kastan, M. B. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1815 · Cited by 857
Chen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735
Self-citationModulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.
Lowe, S. W., & Ruley, H. E. (1993) · Genes & Development · doi:10.1101/gad.7.4.535 · Cited by 666
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
p53 modulation of TFIIH–associated nucleotide excision repair activity
Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.-M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., et al. (1995) · Nature Genetics · doi:10.1038/ng0695-188 · Cited by 554
Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53.
Xiao, H., Pearson, A., Coulombe, B., Truant, R., Zhang, S., Regier, J. L., Triezenberg, S. J., Reinberg, D., Flores, O., & Ingles, C. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.7013 · Cited by 361
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
Lu, H., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5154 · Cited by 301
Dohn, M., Zhang, S., & Chen, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204427 · Cited by 294
Self-citationA Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce Apoptosis
Friedlander, P., Haupt, Y., Prives, C., & Oren, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4961 · Cited by 278
Differential Activation of Target Cellular Promoters by p53 Mutants with Impaired Apoptotic Function
Ludwig, R. L., Bates, S., & Vousden, K. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4952 · Cited by 275
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
Milner, J., Medcalf, E. A., & Cook, A. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243
Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., & Donehower, L. A. (1995) · Nature Genetics · doi:10.1038/ng0395-305 · Cited by 228
Liu, G., & Chen, X. (2002) · Oncogene · doi:10.1038/sj.onc.1205862 · Cited by 207
Self-citationBirch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
High metastatic potential in mice inheriting a targeted p53 missense mutation
Liu, G., McDonnell, T. J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 199
Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194
Ryan, K. M., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3692 · Cited by 184
Horikoshi, N., Usheva, A., Chen, J., Levine, A. J., Weinmann, R., & Shenk, T. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.227 · Cited by 182
Kinetics of p53 Binding to Promoter Sites In Vivo
Szak, S. T., Mays, D., & Pietenpol, J. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3375-3386.2001 · Cited by 179
Blagosklonny, M. V. (2000) · The FASEB Journal · doi:10.1096/fj.99-1078rev · Cited by 170
Ory, K., Legros, Y., Auguin, C., & Soussi, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06656.x · Cited by 163
Nicholls, C. D., McLure, K. G., Shields, M. A., & Lee, P. W. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108815200 · Cited by 152
Hua, Q., Wang, T., Naumovski, L., Lopez, C. D., & Brachmann, R. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205974 · Cited by 138
Molecular Basis for Heterogeneity of the Human p53 Protein
Harris, N., Brill, E., Shohat, O., Prokocimer, M., Wolf, D., Arai, N., & Rotter, V (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.12.4650 · Cited by 79
Tumour p53 mutations exhibit promoter selective dominance over wild type p53
Monti, P., Campomenosi, P., Ciribilli, Y., Iannone, R., Inga, A., Abbondandolo, A., Resnick, M. A., & Fronza, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205250 · Cited by 77
Aurelio, O. N., Kong, X., Gupta, S., & Stanbridge, E. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.770-778.2000 · Cited by 75
Stabilization of the MDM2 Oncoprotein by Mutant p53
Peng, Y., Chen, L., Li, C., Lu, W., Agrawal, S., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000781200 · Cited by 74
In vitro analysis of the dominant negative effect of p53 mutants
Chêne, P. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1897 · Cited by 72
Delia, D., Goi, K., Mizutani, S., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201050 · Cited by 49
Chen, Y., Chen, P., & Lee, W. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6764 · Cited by 38
p73 can suppress the proliferation of cells that express mutant p53
Willis, A. C., Pipes, T., Zhu, J., & Chen, X. (2003) · Oncogene · doi:10.1038/sj.onc.1206505 · Cited by 30
Self-citationJõers, A., Kristjuhan, A., Kadaja, L., & Maimets, T. (1998) · Oncogene · doi:10.1038/sj.onc.1202146 · Cited by 21
The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers
Atema, A., & Chêne, P. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00318-x · Cited by 16
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
Chang, C.-J., Chao, C.-H., Xia, W., Yang, J.-Y., Xiong, Y., Li, C.-W., Yu, W.-H., Rehman, S. K., Hsu, J. L., Lee, H.-H., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2173 · Cited by 745
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations
Merkle, F. T., Ghosh, S., Kamitaki, N., Mitchell, J., Avior, Y., Mello, C., Kashin, S., Mekhoubad, S., Ilic, D., Charlton, M., et al. (2017) · Nature · doi:10.1038/nature22312 · Cited by 506
Metadata
- Authors
- Willis, A., Jung, E. J., Wakefield, T., & Chen, X.
- Venue
- Oncogene
- Published
- 2004-01-26
- Volume
- 23
- Issue
- 13
- Pages
- 2330-2338
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2013126678
- Cited by
- 330
- References
- 47
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.